A new therapeutic armamentarium is emerging in Cell and Gene Therapy. These personalized therapies hold enormous promise for previously untreatable conditions by genetically engineering cells to treat disease, or by altering an individual’s personal DNA to definitively “fix” a tissue abnormality. The complex and customized nature of these therapies presents a challenge because they don’t fit neatly into the current biotech / pharma model for manufacturing drugs. The symposium highlights the Center for Definitive and Curative Medicine (CDCM), a new joint initiative of Stanford Healthcare, Stanford Children’s Health, and the Stanford School of Medicine designed to accelerate cellular therapies. The CDCM provides the organizational and physical infrastructure to support Investigator-initiated clinical translational studies on cell and gene therapy from initial discovery through completion of phase I/II proof-of-concept clinical studies. The symposium highlights the exciting first-in-human cell and gene therapies currently under development at Stanford in bone marrow, skin, cardiac, neural, pancreatic and neoplastic diseases.
Admission free but space is limited.
Register at onlineregistrationcenter.com/CDCM